Hwail Pharmaceutical Co.Ltd (KQ:061250) — Market Cap & Net Worth
Market Cap & Net Worth: Hwail Pharmaceutical Co.Ltd (061250)
Hwail Pharmaceutical Co.Ltd (KQ:061250) has a market capitalization of $386.55 Million (₩570.40 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13691 globally and #407 in its home market, demonstrating a -16.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hwail Pharmaceutical Co.Ltd's stock price ₩6800.00 by its total outstanding shares 83882778 (83.88 Million). Also see Hwail Pharmaceutical Co.Ltd asset portfolio for a full breakdown of the balance sheet.
Hwail Pharmaceutical Co.Ltd Market Cap History: 2015 to 2026
Hwail Pharmaceutical Co.Ltd's market capitalization history from 2015 to 2026. Data shows growth from $111.49 Million to $386.55 Million (12.81% CAGR). Also see Hwail Pharmaceutical Co.Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Hwail Pharmaceutical Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$234.31 Billion | 0.16% | #114 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$234.31 Billion | 0.16% | #114 of 1384 |
Weight: Hwail Pharmaceutical Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hwail Pharmaceutical Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hwail Pharmaceutical Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Hwail Pharmaceutical Co.Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Hwail Pharmaceutical Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Hwail Pharmaceutical Co.Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $111.49 Million | $106.13 Billion | $5.45 Billion | 0.00x | 0.02x |
| 2016 | $142.38 Million | $111.52 Billion | $6.38 Billion | 0.00x | 0.02x |
| 2017 | $122.29 Million | $102.46 Billion | $2.67 Billion | 0.00x | 0.05x |
| 2018 | $119.52 Million | $102.07 Billion | $5.08 Billion | 0.00x | 0.02x |
| 2019 | $122.59 Million | $108.74 Billion | $3.19 Billion | 0.00x | 0.04x |
| 2020 | $238.75 Million | $123.61 Billion | $2.81 Billion | 0.00x | 0.09x |
| 2021 | $148.94 Million | $106.99 Billion | $2.84 Billion | 0.00x | 0.05x |
| 2022 | $158.03 Million | $132.05 Billion | -$6.33 Billion | 0.00x | N/A |
| 2023 | $125.35 Million | $122.54 Billion | $3.86 Billion | 0.00x | 0.03x |
| 2024 | $72.88 Million | $119.76 Billion | $6.48 Billion | 0.00x | 0.01x |
Competitor Companies of 061250 by Market Capitalization
Companies near Hwail Pharmaceutical Co.Ltd in the global market cap rankings as of September 18, 2026. Review 061250 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hwail Pharmaceutical Co.Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Hwail Pharmaceutical Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hwail Pharmaceutical Co.Ltd's market cap moved from $111.49 Million to $ 386.55 Million, with a yearly change of 12.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩386.55 Million | +494.93% |
| 2025 | ₩64.98 Million | -10.84% |
| 2024 | ₩72.88 Million | -41.86% |
| 2023 | ₩125.35 Million | -20.68% |
| 2022 | ₩158.03 Million | +6.11% |
| 2021 | ₩148.94 Million | -37.62% |
| 2020 | ₩238.75 Million | +94.75% |
| 2019 | ₩122.59 Million | +2.58% |
| 2018 | ₩119.52 Million | -2.27% |
| 2017 | ₩122.29 Million | -14.11% |
| 2016 | ₩142.38 Million | +27.71% |
| 2015 | ₩111.49 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Hwail Pharmaceutical Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $386.55 Million USD |
| MoneyControl | $386.55 Million USD |
| MarketWatch | $386.55 Million USD |
| marketcap.company | $386.55 Million USD |
| Reuters | $386.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.